tbuckley/cabot-search huggingface dataset:
Abstract 14422: CXCR4 Identifies Heart Field-specific Cardiac Progenitor Cells
Authors: Emmanouil Tampakakis, Peter Andersen, Hideki Uosaki, Gunsik Cho, Chulan Kwon
Journal: Circulation (2016)

Introduction:  Congenital heart disease is the most common birth defect (1% of live born infants) and most children, who survive to adulthood, will develop severe heart failure. At present, heart transplantation is the only definite treatment for advanced heart failure patients. Heart development involves an early assignment of two distinct cellular populations, called cardiac progenitor cells (CPCs), which generate the first and the second heart field and subsequently the left and right ventricular heart chamber, respectively. Nevertheless, a comprehensive understanding of CPCs for the study of cardiogenesis and the mechanisms of congenital heart defects as well as the development of regenerative cell therapies for heart disease are currently missing.   Study Aim:  We decided to characterize the second heart field population and develop a method for the isolation of chamber-specific CPCs.   Results:  With a candidate approach based on gene expression patterns and lineage trace analysis, we found that CPCs positive for CXC chemokine receptor 4 (CXCR4) are specified in the second heart field and contribute to the right ventricle and outflow tract development. Similarly, we found two distinct populations of CXCR4 positive and negative cells specified in differentiating human and mouse pluripotent stem cell cultures. Gene expression analysis revealed that CXCR+ CPCs express markers of the second heart field (Tbx1, Fgf10 and Fgf8), whereas CXCR4- CPCs express first heart field genes (Tbx5, HCN4 and Nkx2.5). In addition, by single cell analysis we discovered that CXCR4+ CPCs are more proliferative, multipotent and differentiate into all major cardiac lineages (endothelial cells, fibroblasts, cardiomyocytes and smooth muscle cells), whereas CXCR4- CPCs give rise primarily to cardiomyocytes. Finally, using both  in vitro  and  ex vivo  migration assays we identified that the CXCR4 ligand SDF1, is necessary for the proper migration of CPCs towards the right ventricle and outflow tract.   Conclusions:  Collectively, our results provide fundamental insights into the development of the second heart field and demonstrate for the first time the isolation of chamber-specific CPCs using pluripotent stem cells for disease modeling and cell replacement therapies.
TCT-375 Deferred Versus Performed Revascularization in Coronary Stenoses With Gray Zone Fractional Flow Reserve: Data From IRIS FFR Registry
Authors: Do-yoon Kang, Jung-Min Ahn, Cheol Hyun Lee, Osung Kwon, Ungjeong Do, Kyusup Lee, Pil Hyung Lee, Duk-Woo Park, Soo-Jin Kang, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2017)
Abstract #3602: Ongoing phase 1 study of a novel PARP inhibitor, ABT-888 in combination with temozolamide; Pharmacokinetics, safety and anti-tumor activity
Authors: Julian Molina, Charles Erlichman, Donald Northfelt, Janeth Lensing, Vincent Giranda
Journal: Cancer Research (2009)

Background:  Activation of PARP enzymes is an essential step in recognition of DNA damage resulting from chemotherapy agents. Therefore, PARP inhibitors are proposed as sensitizing agents for a variety of DNA damaging agents such as the alkylator temozolomide (TMZ). ABT-888 is a potent PARP inhibitor that may enhance DNA damage induced by chemotherapeutics.  Methods:  A phase I dose escalation study of the combination of ABT-888 and temozolomide is being conducted. This study initially accrued all tumor types but is now restricted to patients with metastatic melanoma and with BRCA-related breast and ovarian cancer. Patients are being treated at escalating doses of ABT-888 with a fixed dose of TMZ.  Results:  25 patients have been accrued to date. One patient with hepatocellular cancer progressive after sorafenib had a partial response. Three patients have stable disease (1 neuroendocrine for 6 cycles and 2 patients with melanoma). One patient died due to disease progression. The main toxicities observed to date, were neutropenia and thrombocytopenia.  Conclusions:  The combination of ABT-888 and temozolomide is well tolerated. This study is currently actively accruing patients with melanoma and BRCA-related breast or ovarian cancer.   Citation Information:  In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 3602.
Induced Pulmonary Tumors in Mice. III. The Role of Chronic Irritation in the Production of Pulmonary Tumors in Strain a Mice
Authors: Michael B. Shimkin, Joseph Leiter
Journal: JNCI Journal of the National Cancer Institute (1940)

Journal Article Induced Pulmonary Tumors in Mice. III. The Role of Chronic Irritation in the Production of Pulmonary Tumors in Strain a Mice Get access Michael B. Shimkin, Michael B. Shimkin assistant surgeon National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Joseph Leiter Joseph Leiter junior chemist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 1, Issue 2, October 1940, Pages 241–254, https://doi.org/10.1093/jnci/1.2.241 Published: 01 October 1940
Altered Brain Developmental Trajectories in Adolescents After Initiating Drinking
Authors: Adolf Pfefferbaum, Dongjin Kwon, Ty Brumback, Wesley K. Thompson, Kevin Cummins, Susan F. Tapert, Sandra A. Brown, Ian M. Colrain, Fiona C. Baker, Devin Prouty, Michael D. De Bellis, Duncan B. Clark, Bonnie J. Nagel, Weiwei Chu, Sang Hyun Park, Kilian M. Pohl, Edith V. Sullivan
Journal: American Journal of Psychiatry (2017)

Objective: The authors sought evidence for altered adolescent brain growth trajectory associated with moderate and heavy alcohol use in a large national, multisite, prospective study of adolescents before and after initiation of appreciable alcohol use. Method: This study examined 483 adolescents (ages 12–21) before initiation of drinking and 1 and 2 years later. At the 2-year assessment, 356 participants continued to meet the study’s no/low alcohol consumption entry criteria, 65 had initiated moderate drinking, and 62 had initiated heavy drinking. MRI was used to quantify regional cortical and white matter volumes. Percent change per year (slopes) in adolescents who continued to meet no/low criteria served as developmental control trajectories against which to compare those who initiated moderate or heavy drinking. Results: In no/low drinkers, gray matter volume declined throughout adolescence and slowed in many regions in later adolescence. Complementing gray matter declines, white matter regions grew at faster rates at younger ages and slowed toward young adulthood. Youths who initiated heavy drinking exhibited an accelerated frontal cortical gray matter trajectory, divergent from the norm. Although significant effects on trajectories were not observed in moderate drinkers, their intermediate position between no/low and heavy drinkers suggests a dose effect. Neither marijuana co-use nor baseline volumes contributed significantly to the alcohol effect. Conclusions: Initiation of drinking during adolescence, with or without marijuana co-use, disordered normal brain growth trajectories. Factors possibly contributing to abnormal cortical volume trajectories include peak consumption in the past year and family history of alcoholism.
Gemcitabine plus cisplatin and S-1 for biliary tract cancer: a single institute analysis
Authors: Osamu Maeda, Tomoya Shimokata, Takefumi Mizutani, Megumi Inoue, Ayumu Matsuoka, Akiko Ota, Takashi Mizuno, Tomoki Ebata, Masato Nagino, Yuichi Ando
Journal: Annals of Oncology (2017)
Review of cases with exposure to anti-cancer drugs and the alteration of fixation method using I-cut gauze in CV port
Authors: Satoshi Hibi, Yuko Shirokawa, Chiaki Koga, Megumi Kabeya, Satoshi Kayukawa, Ryuichi Furuta, Takae Kataoka, Shu Yuasa, Kenji Ina
Journal: Annals of Oncology (2017)
Abstract SY14-03: Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies
Authors: Stephan W. Morris
Journal: Cancer Research (2010)

Abstract Citation Format: Stephan W. Morris. Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies [abstract]. In: Proceedings of the AACR 101st Annual Meeting 2010; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr SY14-03
Integrated pathogen load and dual transcriptome analysis of systemic host-pathogen interactions in severe malaria
Authors: Hyun Jae Lee, Athina Georgiadou, Michael Walther, Davis Nwakanma, Lindsay B. Stewart, Michael Levin, Thomas D. Otto, David J. Conway, Lachlan J. Coin, Aubrey J. Cunnington
Journal: Science Translational Medicine (2018)

Host and parasite RNA sequencing is combined with parasite load estimates to reveal mechanisms associated with human severe malaria.
Prenatal and early-life triclosan and paraben exposure and allergic outcomes
Authors: Kathleen Lee-Sarwar, Russ Hauser, Antonia M. Calafat, Xiaoyun Ye, George T. O'Connor, Megan Sandel, Leonard B. Bacharier, Robert S. Zeiger, Nancy Laranjo, Diane R. Gold, Scott T. Weiss, Augusto A. Litonjua, Jessica H. Savage
Journal: Journal of Allergy and Clinical Immunology (2017)
Guías BICHAT para el manejo clínico del carbunco y del carbunco relacionado con el bioterrorismo
Authors: P Bossi, A Tegnell, A Baka, F van Loock, J Hendriks, A Werner, H Maidhof, G Gouvras
Journal: Eurosurveillance (2004)

El Bacillus anthracis formador de esporas se considera una de las mas graves armas biologicas en potencia. Los ultimos casos de carbunco producidos por una emision intencionada declarados en 2001 en Estados Unidos ponen de manifiesto la necesidad de una
Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study
Authors: Min Jun, Lisa M Lix, Madeleine Durand, Matt Dahl, J Michael Paterson, Colin R Dormuth, Pierre Ernst, Shenzhen Yao, Christel Renoux, Hala Tamim, Cynthia Wu, Salaheddin M Mahmud, Brenda R Hemmelgarn
Journal: BMJ (2017)

<b>Objective</b>&nbsp;To determine the safety of direct oral anticoagulant (DOAC) use compared with warfarin use for the treatment of venous thromboembolism. <b>Design</b>&nbsp;Retrospective matched cohort study conducted between 1 January 2009 and 31 March 2016. <b>Setting</b>&nbsp;Community based, using healthcare data from six jurisdictions in Canada and the United States. <b>Participants</b>&nbsp;59 525 adults (12 489 DOAC users; 47 036 warfarin users) with a new diagnosis of venous thromboembolism and a prescription for a DOAC or warfarin within 30 days of diagnosis. <b>Main outcome measures</b>&nbsp;Outcomes included hospital admission or emergency department visit for major bleeding and all cause mortality within 90 days after starting treatment. Propensity score matching and shared frailty models were used to estimate adjusted hazard ratios of the outcomes comparing DOACs with warfarin. Analyses were conducted independently at each site, with meta-analytical methods used to estimate pooled hazard ratios across sites. <b>Results</b>&nbsp;Of the 59 525 participants, 1967 (3.3%) had a major bleed and 1029 (1.7%) died over a mean follow-up of 85.2 days. The risk of major bleeding was similar for DOAC compared with warfarin use (pooled hazard ratio 0.92, 95% confidence interval 0.82 to 1.03), with the overall direction of the association favouring DOAC use. No difference was found in the risk of death (pooled hazard ratio 0.99, 0.84 to 1.16) for DOACs compared with warfarin use. There was no evidence of heterogeneity across centres, between patients with and without chronic kidney disease, across age groups, or between male and female patients. <b>Conclusions</b>&nbsp;In this analysis of adults with incident venous thromboembolism, treatment with DOACs, compared with warfarin, was not associated with an increased risk of major bleeding or all cause mortality in the first 90 days of treatment. <b>Trial registration</b>&nbsp;Clinical trials NCT02833987.
OA03.07 Dabrafenib and Trametinib Combination Therapy versus Docetaxel in Previously Treated Metastatic NSCLC: an Adjusted Indirect Comparison
Authors: M. Sasane, J. Li, P. Zhang, J. Zhao, M.L. Ricculli, J. Signorovitch
Journal: Journal of Thoracic Oncology (2017)
Trump declares opioid public health emergency but no extra money
Authors: Bob Roehr
Journal: BMJ (2017)

Opioids are the “worst drug crisis in American history,” claiming 175 lives every day, said President Donald Trump in declaring a public health emergency on Thursday 26 October.1

“No part of our society—not young or old, rich or poor, urban or rural—has been spared this plague” of addiction and death, he said.

Trump announced a broad series of actions that the federal government has and will be taking to rein in the supply of illegal drugs, to shift from a legal to a medical approach to the problems of addiction, and to expand treatment for substance misuse.

But he stopped short of declaring a national state of emergency, as was done recently for states affected by hurricanes and …
TCT-368 The Drug-eluting Absorbable Magnesium Vascular Scaffold in Complex Coronary Bifurcations: Insights from an In-Vivo Multimodality Imaging study
Authors: Johan Bennett, Maarten Vanhaverbeke, Nick Hiltrop, Nina Vanden Driessche, Peter Sinnaeve, Keir McCutcheon, Tom Adriaenssens, Walter Desmet, Christophe Dubois
Journal: Journal of the American College of Cardiology (2017)
Perspectivas de un Centro Europeo para la prevención y el control de enfermedades
Authors: M Kokki, R Haigh
Journal: Eurosurveillance (2004)

Acuerdo sobre la Regulacion El dia 30 de Marzo de 2004, el Consejo finalmente dio su acuerdo a la Regulacion instaurando el nuevo Centro Europeo para la Prevencion y Control de las Enfermedades. 
Desde la propuesta de la Comision en Julio de 2003, fueron suficientes ocho meses de negociacion para llegar a un acuerdo final entre el Parlamento y el Consejo de Europa. Este tiempo no seria un record para un acuerdo sobre una nueva legislacion europea, pero considerando el tipo de legislacion que eso exige - el establecimiento de una nueva institucion comunitaria con financiacion permanente y participacion obligatoria de los Estados miembros - probablemente lo es. Ahora viene el paso siguiente: la implementacion practica de la Regulacion. Las primeras prioridades son la eleccion del Director y del emplazamiento en Estocolmo. La regulacion fijo una serie ambiciosa de condiciones para que el Centro sea operacional en Mayo de 2005: poner en marcha el Comite de direccion, organizar el programa de trabajo para 2005 y responder a las numerosas exigencias organizativas. 
Si el Centro debe funcionar en menos de un ano, es esencial tomar decisiones sobre estos aspectos practicos muy importantes. Pero todavia es mas fundamental la cuestion de los mandatos, tanto para el presente como para el futuro; como se podra atenderlos, en los primeros anos, con un pequeno presupuesto inicial de diez millones de euros, financiado en parte por el Programa de Salud Publica, y como podran ellos complementar las iniciativas que existen al nivel internacional y comunitario o con paises terceros.
Fibrinogen Activates BMP Signaling in Oligodendrocyte Progenitor Cells and Inhibits Remyelination after Vascular Damage
Authors: Mark A. Petersen, Jae Kyu Ryu, Kae-Jiun Chang, Ainhoa Etxeberria, Sophia Bardehle, Andrew S. Mendiola, Wanjiru Kamau-Devers, Stephen P.J. Fancy, Andrea Thor, Eric A. Bushong, Bernat Baeza-Raja, Catriona A. Syme, Michael D. Wu, Pamela E. Rios Coronado, Anke Meyer-Franke, Stephanie Yahn, Lauriane Pous, Jae K. Lee, Christian Schachtrup, Hans Lassmann, Eric J. Huang, May H. Han, Martina Absinta, Daniel S. Reich, Mark H. Ellisman, David H. Rowitch, Jonah R. Chan, Katerina Akassoglou
Journal: Neuron (2017)
An Image Analysis Resource for Cancer Research: PIIP—Pathology Image Informatics Platform for Visualization, Analysis, and Management
Authors: Anne L. Martel, Dan Hosseinzadeh, Caglar Senaras, Yu Zhou, Azadeh Yazdanpanah, Rushin Shojaii, Emily S. Patterson, Anant Madabhushi, Metin N. Gurcan
Journal: Cancer Research (2017)

Abstract Pathology Image Informatics Platform (PIIP) is an NCI/NIH sponsored project intended for managing, annotating, sharing, and quantitatively analyzing digital pathology imaging data. It expands on an existing, freely available pathology image viewer, Sedeen. The goal of this project is to develop and embed some commonly used image analysis applications into the Sedeen viewer to create a freely available resource for the digital pathology and cancer research communities. Thus far, new plugins have been developed and incorporated into the platform for out of focus detection, region of interest transformation, and IHC slide analysis. Our biomarker quantification and nuclear segmentation algorithms, written in MATLAB, have also been integrated into the viewer. This article describes the viewing software and the mechanism to extend functionality by plugins, brief descriptions of which are provided as examples, to guide users who want to use this platform. PIIP project materials, including a video describing its usage and applications, and links for the Sedeen Viewer, plug-ins, and user manuals are freely available through the project web page: http://pathiip.org. Cancer Res; 77(21); e83–86. ©2017 AACR.
Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response
Authors: Qiong Xue, Emily Bettini, Patrick Paczkowski, Colin Ng, Alaina Kaiser, Timothy McConnell, Olja Kodrasi, Máire F. Quigley, James Heath, Rong Fan, Sean Mackay, Mark E. Dudley, Sadik H. Kassim, Jing Zhou
Journal: Journal for ImmunoTherapy of Cancer (2017)

<h3>Background</h3> It remains challenging to characterize the functional attributes of chimeric antigen receptor (CAR)-engineered T cell product targeting CD19 related to potency and immunotoxicity ex vivo, despite promising in vivo efficacy in patients with B cell malignancies. <h3>Methods</h3> We employed a single-cell, 16-plex cytokine microfluidics device and new analysis techniques to evaluate the functional profile of CD19 CAR-T cells upon antigen-specific stimulation. CAR-T cells were manufactured from human PBMCs transfected with the lentivirus encoding the CD19-BB-z transgene and expanded with anti-CD3/anti-CD28 coated beads. The enriched CAR-T cells were stimulated with anti-CAR or control IgG beads, stained with anti-CD4 RPE and anti-CD8 Alexa Fluor 647 antibodies, and incubated for 16&nbsp;h in a single-cell barcode chip (SCBC). Each SCBC contains ~12,000 microchambers, covered with a glass slide that was pre-patterned with a complete copy of a 16-plex antibody array. Protein secretions from single CAR-T cells were captured and subsequently analyzed using proprietary software and new visualization methods. <h3>Results</h3> We demonstrate a new method for single-cell profiling of CD19 CAR-T pre-infusion products prepared from 4 healthy donors. CAR-T single cells exhibited a marked heterogeneity of cytokine secretions and polyfunctional (2+ cytokine) subsets specific to anti-CAR bead stimulation. The breadth of responses includes anti-tumor effector (Granzyme B, IFN-γ, MIP-1α, TNF-α), stimulatory (GM-CSF, IL-2, IL-8), regulatory (IL-4, IL-13, IL-22), and inflammatory (IL-6, IL-17A) functions. Furthermore, we developed two new bioinformatics tools for more effective polyfunctional subset visualization and comparison between donors. <h3>Conclusions</h3> Single-cell, multiplexed, proteomic profiling of CD19 CAR-T product reveals a diverse landscape of immune effector response of CD19 CAR-T cells to antigen-specific challenge, providing a new platform for capturing CAR-T product data for correlative analysis. Additionally, such high dimensional data requires new visualization methods to further define precise polyfunctional response differences in these products. The presented biomarker capture and analysis system provides a more sensitive and comprehensive functional assessment of CAR-T pre-infusion products and may provide insights into the safety and efficacy of CAR-T cell therapy.
TCT-533 Optical coherence tomography comparison of fibrous plaque morphology in hemodynamically relevant intermediate coronary stenoses as determined by fractional flow reserve
Authors: Mariusz Tomaniak, Janusz Kochman, Lukasz Koltowski, Dorota Ochijewicz, Arkadiusz Pietrasik, Jacek Jakala, Klaudia Proniewska, Krzysztof Malinowski, Grzegorz Opolski
Journal: Journal of the American College of Cardiology (2017)
Abstract 14909: Hydrogen Peroxide-Responsive Nanoparticles Reduce Myocardial Ischemia/Reperfusion Injury
Authors: Soochan Bae, Changsun Kang, Minhyung Park, Mohammed A Samad, Taehi Kang, Qingen Ke, Dongwon Lee, Peter M Kang
Journal: Circulation (2015)

During myocardial ischemia/reperfusion (I/R), a large amount of reactive oxygen species (ROS) is produced which causes oxidative stress and leads to severe cellular and tissue damage. In particular, overproduction of hydrogen peroxide (H2O2) is considered as a main cause of I/R-mediated tissue damage by inducing inflammation and apoptosis. Therefore, rapid elimination of H2O2 and suppression of oxidative stress are thought to be reasonable strategies to treat myocardial I/R injury. Recently, we generated novel H2O2-responsive antioxidant polymer nanoparticles (PVAX and HPOX) that are able to target the site of ROS overproduction and impede the progression of oxidative stress-associated diseases. In this study, PVAX nanoparticles were selected as therapeutic agents for myocardial I/R injury based on the results of direct comparison studies in vitro and in vivo. To explore therapeutic effect of PVAX on cardiac I/R injury, cardiac function 2 weeks after reperfusion was evaluated. A single dose of PVAX (3mg/kg) showed a significant improvement in both cardiac output (8.1± 0.7 vs. 3.4±0.3) and fraction shortening (43.8± 0.9 vs. 31.2±3.8) compared with poly (lactic-co-glycolic acid) (PLGA) particle, a lacking H2O2 responsible nanoparticle. Consistent with cardiac function evaluation, PVAX significantly reduced the myocardial infarction /area at risk compared with PLGA (48.7±4.2 vs.14.5±2.1). In addition, PVAX effectively reduced caspase-3 activation (2.6±0.1 vs.1.4±0.1) and TUNEL-positive cells (8.2±1.8 vs. 2.7±0.6) compared with PLGA. Furthermore, PVAX significantly decreased TNF-α (5.5±0.4 vs. 3.0±0.3) and MCP-1 (2.3±0.1 vs. 1.4±0.1) mRNA levels. To explore the antioxidant effect of PVAX by scavenging ROS, dihydroethidium (DHE) staining was used as an indicator of ROS generation. PVAX effectively suppressed the generation of ROS caused by I/R while a number of DHE-positive cells were observed in a group of PLGA I/R. In addition, PVAX significantly reduced the level of NADPH oxidase (NOX) 2 and 4 expression, which favors the reduction in ROS generation after I/R. Taken together, these results suggest that H2O2-responsive antioxidant PVAX has tremendous potential as a therapeutic agent for myocardial I/R injury.